Children with Bardet-Biedl Syndrome Show Disrupted Appetite Hormones That Drive Obesity
Children with Bardet-Biedl syndrome have elevated ghrelin and leptin levels but appear resistant to appetite-suppressing signals, helping explain why obesity is a hallmark of this rare genetic disorder.
Quick Facts
What This Study Found
BBS patients had significantly higher BMI than controls. Plasma levels of acylated ghrelin, total ghrelin, and obestatin were slightly elevated compared to controls, as was the acyl-to-total ghrelin ratio. Most notably, leptin levels were significantly elevated in BBS patients.
Normally, high leptin levels signal the brain to reduce appetite, and ghrelin should decrease after eating. In BBS patients, these negative feedback mechanisms appeared broken — ghrelin remained elevated despite adequate nutrition, and the body appeared resistant to leptin's appetite-suppressing effects. This shifts the hormonal balance toward constant hunger signaling.
Key Numbers
How They Did This
The researchers measured five appetite-related hormones (total ghrelin, acylated ghrelin, obestatin, leptin, and adiponectin) in blood samples from eight children with BBS. Results were compared to healthy controls and analyzed in relation to body mass index and height. This was a case-control study design.
Why This Research Matters
Understanding why children with BBS develop severe obesity is critical for developing targeted treatments. This study provides evidence that the obesity isn't simply from overeating — it's driven by measurable hormonal imbalances in peptide signaling. This shifts the conversation from behavioral to biological and opens the door for potential peptide-based interventions like leptin sensitizers or ghrelin modulators.
The Bigger Picture
Bardet-Biedl syndrome is one of several rare genetic obesity syndromes (alongside Prader-Willi and MC4R deficiency) that have illuminated how peptide hormones control body weight. The discovery of leptin resistance in BBS contributed to broader understanding of why some people's bodies ignore fullness signals — a mechanism now recognized as relevant to common obesity as well. This research helped pave the way for drugs like setmelanotide, which targets the melanocortin pathway downstream of leptin.
What This Study Doesn't Tell Us
The study included only 8 children with BBS, which is a very small sample size even for a rare disease. The cross-sectional design captures hormone levels at one point in time, not how they change over the course of disease. The study measured circulating hormone levels but did not directly assess receptor sensitivity or brain responses to these hormones.
Questions This Raises
- ?Could leptin-sensitizing drugs help restore appetite regulation in BBS patients?
- ?Do the specific BBS gene mutations correlate with the degree of hormonal disruption?
- ?Would ghrelin receptor antagonists reduce hunger drive in BBS patients?
Trust & Context
- Key Stat:
- Leptin resistance BBS patients had significantly elevated leptin yet still experienced constant hunger, indicating their brains couldn't respond to the fullness signal
- Evidence Grade:
- This is a small case-control study with only 8 BBS patients. While it provides valuable mechanistic insights about hormonal disruption, the small sample limits generalizability and statistical power.
- Study Age:
- Published in 2012, this study predates the approval of setmelanotide (2020) for BBS-related obesity. The hormonal findings remain valid and helped build the scientific case for melanocortin pathway-targeted therapies.
- Original Title:
- Obesity in patients with Bardet-Biedl syndrome: influence of appetite-regulating hormones.
- Published In:
- Pediatric nephrology (Berlin, Germany), 27(11), 2065-2071 (2012)
- Authors:
- Büscher, Anja K, Cetiner, Metin, Büscher, Rainer(2), Wingen, Anne-Margret, Hauffa, Berthold P, Hoyer, Peter F
- Database ID:
- RPEP-01912
Evidence Hierarchy
Frequently Asked Questions
What is Bardet-Biedl syndrome?
BBS is a rare genetic disorder caused by mutations in BBS genes that affect cellular structures called cilia. Major features include severe childhood obesity, vision loss, kidney abnormalities, extra fingers or toes, and learning difficulties. Obesity typically develops in early childhood and is one of the defining features of the condition.
Why can't children with BBS simply eat less to control their weight?
This study shows that BBS disrupts the peptide hormones that normally control appetite. Their bodies produce high levels of leptin (the 'I'm full' hormone), but their brains appear resistant to it. Meanwhile, ghrelin (the hunger hormone) stays elevated when it should decrease. This creates a biological drive to eat that willpower alone cannot easily overcome.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01912APA
Büscher, Anja K; Cetiner, Metin; Büscher, Rainer; Wingen, Anne-Margret; Hauffa, Berthold P; Hoyer, Peter F. (2012). Obesity in patients with Bardet-Biedl syndrome: influence of appetite-regulating hormones.. Pediatric nephrology (Berlin, Germany), 27(11), 2065-2071. https://doi.org/10.1007/s00467-012-2220-y
MLA
Büscher, Anja K, et al. "Obesity in patients with Bardet-Biedl syndrome: influence of appetite-regulating hormones.." Pediatric nephrology (Berlin, 2012. https://doi.org/10.1007/s00467-012-2220-y
RethinkPeptides
RethinkPeptides Research Database. "Obesity in patients with Bardet-Biedl syndrome: influence of..." RPEP-01912. Retrieved from https://rethinkpeptides.com/research/buscher-2012-obesity-in-patients-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.